Events and Presentations
Symposium 238: Immuno-Mediated Diseases of the GI Tract: Where Do We Stand?
Sara Elhag, Ph.D., Associate Manager Translational Pharmacology at Immunic, will present data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a poster presentation.
- Poster Title: First-in-Human Trial of IMU-856, an Orally Available Epigenetic Modulator of Barrier Function and Regeneration for the Treatment of Celiac Disease
- Abstract ID: S238_1375
- Poster Number: 15